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The second commonest cause of cancer death in the Western world
is attributed to prostate cancer (Jensen et al, 1990). It is well docu-
mented that prostatic carcinoma shows a predilection to metasta-
size to the bone marrow (Jacobs, 1983). Metastatic prostate cancer
remains an incurable disease and as such, is a massive clinical
problem. There is clearly a need to elucidate the factors underlying
the spread of prostate cancer, particularly to the skeleton. 
It has been suggested that the bone marrow microenvironment
is conducive to the growth of prostate cancer cells, which non-
selectively enter the bone marrow from the circulation (Galasko,
1981; Jacobs, 1983; Paget, 1989; Body, 1992). However, the strik-
ingly consistent pattern of prostate metastasis within the red
marrow suggests that this process may in fact be regulated (Fidler
et al, 1978). The mechanism of metastasis is a complex multi-step
process that is not fully understood. One critical step in this mech-
anism may be the attachment to and extravasation through
endothelial barriers by malignant cells possibly leading to selec-
tive metastatic sites. Tumour cell binding to endothelium involves
two distinct steps, an initial docking step mediated via
lectin–carbohydrate interactions followed by an integrin-mediated
locking step (Honn and Tang, 1992). Several endothelial and
tumour adhesion molecules have been associated with metastasis.
In particular the integrins b1, a2 and a5 have been shown to be
expressed by prostate epithelial cells and bone marrow cells
(Soligo et al, 1990; Nagle et al, 1994; Rokhlin and Cohen, 1995).
The carbohydrate sialyl Lewis X has also been associated with
breast and lung cancer metastasis and its ligand P selectin is found
on endothelial cells (Soligo et al, 1990). Some lung, brain, liver
and ovary metastatic tumour cells have been demonstrated to bind
selectively to endothelial cells isolated from lung, brain, liver and
ovary respectively (Nicolson and Winkelhake, 1975; Auerbach 
et al, 1987). These studies suggest an active regulatory role for the
endothelium in metastasis (Zetter, 1990). 
We have shown previously that primary prostatic epithelia from
both benign and malignant tissue show an accelerated growth rate
within bone marrow stroma compared to control stroma (Lang 
et al, 1998) and also that integrin a2b1 is a major contributor to
the binding of primary prostatic epithelial cells to bone marrow
stroma (Lang et al, 1997). This pattern of primary prostatic epithe-
lial cell adhesion (a2b1) is mimicked by the prostate cell line, PC3
(Kostenuik et al, 1996) and our experiments were therefore
conducted with this cell line. These studies have now been
extended to develop a model to investigate the interactions of
prostatic epithelial cells (primary and cell lines) with the bone
marrow endothelium. 
MATERIALS AND METHODS 
Materials 
General chemicals were purchased from Sigma (Poole, UK).
Tissue culture media and supplements were obtained from Gibco
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(EGM-2) from Bio Whittaker (Wokingham, UK) and HAMS-F12
from PAA Laboratories (Linz, Austria). Fetal calf serum (FCS)
was purchased from Advanced Protein Products (Briely Hill West,
UK), horse serum from Autogen Bioclear (Wiltshire, UK) and
Worthington Collagenase from Lorne Laboratories (Twyford,
UK). 
Antibodies 
Mouse monoclonal anti-vimentin, anti-pan-cytokeratin (clone
C11), anti P selectin and anti-von-Willebrand factor antibodies
were all obtained from Sigma. Mouse monoclonal anti b1, a2, a4,
a5 integrins and sialy Lewis X (CD15s) antibodies were from
Becton Dickinson (Oxford, UK). Anti-CD31, mouse IgG, rabbit
anti-mouse horse-radish peroxidase and swine anti-rabbit horse-
radish peroxidase were all from Dako (High Wycombe, UK).
Monoclonal anti b4 integrin was from Serotec (Oxford, UK) and
rabbit anti-human cytokeratin from Biogenesis (Poole, UK). 
Tissue collection 
Bone marrow aspirates were collected from patients undergoing
surgery for benign diseases after informed consent had been
obtained. Prostate tissue was collected from patients with benign
prostatic hyperplasia or adenocarcinoma of the prostate under-
going transurethral resection for bladder outflow obstruction. Each
individual prostatic chip was halved, half was sent for histological
analysis for the presence/absence of tumour cells; the remaining
was used for tissue culture. 
Bone marrow stromal culture 
Long-term bone marrow stroma (BMS) cultures were established
according to the protocol of Coutinho et al (1993). In brief, bone
marrow samples were depleted of red blood cells by using a 0.1%
(w/v) methylcellulose solution. The remaining cells were then
seeded at 2 ´ 106 cell ml–1 in bone marrow growth medium
(Iscove’s modified Dulbecco’s medium (350 mOsm), 10% FCS,
10% horse serum, 5 ´ 10–7 M hydrocortisone and 1%
antibiotic/antimycotic solution). The cultures were grown at 33˚C
in 5% CO2 in air. Growing cultures were fed weekly by removal of
half the medium followed by replacement with fresh growth
medium. After approximately 4 weeks of growth confluent
haemopoietically active cultures were observed (containing a
heterogeneous mix of cells including adipocytes, macrophages,
endothelial and fibroblasts). 
Bone marrow endothelial cell isolation and culture 
Bone marrow endothelial cells (BME) were isolated by modifying
the technique of Masek and Sweetenham (1994). Briefly, bone
marrow aspirates (10–20 ml) were diluted (1:1 v/v) into
Dubecco’s modification of Eagles medium (DMEM) containing
heparin (30–40 U ml–1). The marrow was then filtered through a
70 mm mesh strainer, washed 2´ with Hanks balanced salt solution
(HBSS). Red cells were lysed using ammonium chloride lysis
buffer. The remaining cells were then centrifuged at 200 g for 
5 min and re-suspended in PBS (10 mM phosphate buffer
(pH 7.3), 137 mM NaCl and 3 mM KCL) containing 1% bovine
serum albumin (BSA) and 5 mM EDTA (wash buffer). Magnetic
Dyna beads (Dynal, Wirral, UK) were coupled to Ulex europaeus
agglutinin-1 (UEA-1) (Sigma, Poole, UK) as described by Jackson
et al (1990). The coated dyna beads were mixed with the cell
suspension at a bead to cell ratio of 5 beads per endothelial cell
(assuming endothelial cells comprise approximately 1% of the
total cell count (Masek and Sweetenham, 1994) for 10 min at 4˚C
on a rotary mixer. The BME cells bound to the UEA-1 coated
beads were washed 5´ by resuspending in 5 ml of wash buffer and
mixing for 1 min followed by separation using a magnetic particle
concentrator (Dynal, Wirral, UK). Finally the isolated endothelial
cells were re-suspended in endothelial plating media containing
5% FCS and seeded into a 12.5 ml fibronectin coated (50 mg ml–1)
tissue culture flask. After 24 h the media was removed and
replaced with EGM-2 containing 5% FCS. The cells were grown
to confluence at 37˚C in 5% CO2 in air. Cells were passaged up to
4 times using trypsin for endothelial cell cultures (Sigma, Poole,
UK). The endothelial nature of the cells was confirmed by
immunohistochemical staining for known endothelial markers. 
Prostatic epithelial and fibroblast cell culture 
Prostatic epithelia were isolated and characterized as described by
Lang et al (1998). Briefly, prostate specimens were minced and
incubated over night in collagenase (200 U ml–1) in RPMI 1640
supplemented with 5% FCS on a shaking platform at 37˚C. The
solution was then broken up by pipetting and washed once in
RPMI 1640 medium with 5% FCS at 800 g for 5 min. The pellet
was then resuspended in 0.1% (w/v) trypsin and incubated for a
further 30 min at 37˚C on a shaker. The final digest was washed 3
times then centrifuged at 360 g for 1 min to produce a pellet
enriched for epithelia. The epithelial cells were resuspended in
serum-free Keratinocyte media (Gibco) and passed through a 
40 mm cell sieve to give a single cell suspension. The epithelial
cells were frozen in FCS and 10% DMSO until use. Epithelial
cells have been shown previously to contribute to between
30–80% of the cell population as assessed by fluorescent-activated
cell sorting of cytokeratin positive cells (Lang et al, 1998) (conta-
minating cell types were mainly blood cells with a few remaining
fibroblasts). Subsequent growth of epithelia was favoured by
using serum-free keratinocyte media. 
Culture of cell lines 
Human umbilical vein endothelial cells (HUVEC) and lung
microvascular cells (Hs888Lu) were obtained from the European
Collection of Animal Cell Cultures (Porton Down, UK). HUVEC
and Hs888Lu cells were cultured in EGM-2. Cells were passaged
using trypsin for endothelial cells, HUVEC cells were used up to
passage 8 and Hs888Lu cells up to passage 4. The prostatic carci-
noma cell line, PC3, was routinely cultured in HAMS-F12 supple-
mented with 2 mM glutamine with 7% FCS and the normal
prostate cell line, PNT2-C2 (Berthon et al, 1995), in RPMI-1640
containing 2 mM glutamine with 10% FCS. 
Binding assay 
Endothelium (1 ´ 105 cells ml–1) or stroma (confluent T-12.5
plate–1) were seeded into 96-well plates (200 ml well–1) and grown
to confluence. Once confluent half the media was removed and
replaced with 100 ml of Hams-F12 with and without the addition
of 5000 PC3 or primary prostatic epithelial cells. The epithelial
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removal of any unbound cells by washing 3 times with PBS.
Subsequently, the plates were fixed with a mixture of
methanol:acetone (1:1, v:v) for 20 min at –20˚C. The fixative was
then removed and the plates allowed to air dry. Epithelial cell
binding was assessed by staining for cytokeratin, as follows:
endogenous peroxidases were blocked by the addition of 3% H2O2
in PBS for 30 min at room temperature. The plate was subse-
quently washed with PBS/0.05% Tween 20 (PBS-T). Non-specific
binding sites were blocked with 20% rabbit serum in 1%
BSA/PBS for 1 h at room temperature. After 3 washes with PBS-
T, the cells were then incubated with a mouse anti-human pan
cytokeratin antibody diluted 1:3200 (v:v) for 1 h at room tempera-
ture. Following washing, a secondary horse-radish peroxidase-
linked rabbit anti-mouse antibody was added and allowed to bind
for a further 1 h. The plate was then washed once with PBS-T,
once with dH2O and once with ABTS buffer (Boehringer
Mannheim, Germany) followed by the addition of the ABTS
substrate (Boehringer Mannheim, Germany). Finally, the substrate
was developed for 45 min at room temperature and the optical
density read at 405 nm. The number of bound epithelial cells was
expressed as the optical density of cytokeratin fluorescence, which
was shown to be linearly related (results not shown). 
Inhibition studies 
PC3 cells were pre-incubated with antibodies against b4, b1, a2,
a4 and a5 integrins and sialy Lewis X for 30 min at 37˚C. Control
cells were incubated with mouse IgG. All antibodies were used at
20 mgm l –1 (Lang et al, 1997). The cells were then added to
confluent monolayers of BME at a density of 5 ´ 104 well–1.
Binding was allowed to take place for 1 h at 37˚C. The plates were
then washed 3´ with PBS and fixed with methanol:acetone (1:1,
v:v) for 20 min at –20˚C. BME were also pre-treated with anti-
bodies against P selectin, CD31 and VCAM-1 (20 m g ml–1) for 
30 min. 5 ´ 104 PC3 well–1 were then added and incubated for 1 h.
The plates were then washed and fixed as stated above. PC3
binding was measured using the binding assay with the following
modifications; non-specific binding sites were blocked with 5%
human serum in 1% BSA/PBS, the mouse anti-human cytokeratin
antibody was substituted by a rabbit anti-human cytokeratin anti-
body (1:250) to prevent any cross-reactivity with the inhibitory
antibodies and the secondary antibody was replaced with a swine
anti-rabbit horse-radish peroxidase antibody (1:1000). The plates
were then developed as before. 
Immunocytochemistry 
Cells to be stained were grown in 8-well glass chamber slides until
confluent. The cells were then fixed with methanol:acetone (1:1,
v:v) at –20˚C for 20 min. All staining was performed at room
temperature in a humidified chamber. Non-specific binding sites
were blocked by the addition of 20% rabbit serum or swine serum
(depending on the origin of the secondary antibody) in 1%
BSA/PBS for 1 h. Wells were subsequently washed 3 times with
PBS. Primary antibodies were then added and allowed to bind for
1 h. Endogenous peroxidases were inhibited with 1% H2O2 in PBS
for 10–15 min followed by 3 washes with PBS. Rabbit anti-mouse
or swine anti-rabbit biotinylated secondary antibodies (depending
on the origin of the primary antibody) were then added (1:400) for
40 min. Following washing with PBS, Vectorstain ABC-HRP
(Vector Laboratories, Peterborough, UK) was added and allowed
to bind for 15 min then washed. Positively stained cells were then
observed by the addition of DAB (Sigma, Poole, UK) for 5–15
min. The slides were washed in dH2O and counter stained with 1%
Gills haematoxylin. 
Invasion assay 
Invasion chambers were prepared by coating cell culture inserts 
(8 mm pore size, Becton Dickinson) with 100 ml of Matrigel
(Becton Dickinson) diluted 1:45 (v:v) with Dulbecco’s modified
Eagles Medium (DMEM, Life Technologies). The inserts were
incubated over night at 37˚C. Growth media was aspirated from
confluent endothelial/stromal cultures grown in 24-well plates and
replaced with 1 ml DMEM supplemented with 0.1% BSA.
Matrigel-coated inserts were placed over the endothelial/stromal
cultures. Epithelial cells (PC3, PNT2-C2 or BPH) were prepared in
DMEM supplemented with 0.1% (w:v) BSA to a cell concentration
of 2 ´ 105 cells ml–1 and 0.5 ml of this cell suspension was added to
each insert. Control wells were prepared which contained no
endothelial/stromal monolayer. Each experiment was carried out in
triplicate. The invasion assay was left for 18 h after which cells that
had not invaded were removed from the top of the insert by scrub-
bing with a cotton bud. The inserts were then fixed in methanol for
10 min and then stained with 0.1% (w:v) crystal violent (Sigma).
Cells that had invaded to the underside of the insert were then
counted according to the manufacturer’s instructions. 
Statistics 
All assays were compared by use of the two-tailed Student’s t-test.
A threshold of significance was set at P < 0.05. 
RESULTS 
Characterization bone marrow endothelial cells 
The cells showed the characteristic spindle-shaped morphology
described previously by Masek and Sweetenham (1994). UEA-1
coated magnetic beads can be seen still attached to many of the
endothelial cells (Figure 1A, mouse IgG1 negative control). The
endothelial nature of the cultured cells was confirmed by staining
for von-Willebrand factor (Figure 1B) the major marker for
endothelial cells. Cultures from up to 4 passages were used for
assays. Table 1 summarizes the staining characteristics of bone
marrow endothelium compared to human umbilical vein endothe-
lial and PC3 cells. 
Binding assay 
An assay to measure the binding characteristics of prostatic epithe-
lial cells to endothelium or stroma was developed. The assay was
initially established using the prostatic cell line PC3. This partic-
ular cell line was chosen as it was derived from a human prostatic
bone marrow metastasis and has been shown to metastasize in
about 30% of cases when injected subcutaneously into nude mice
(Shevrin et al, 1989). It has also been shown to interact with bone
marrow stroma in an identical manner to primary prostatic epithe-
lial cells (Kostenuik et al, 1996; Lang et al, 1997). 
Binding of PC3 cells to HUVEC, BMS (positive control) or
BME was measured over 4 h after which levels began to plateau
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felt that cell division of bound epithelial cells would lead to falsely
high levels being measured). The majority of cells bound within
the first 60 min. Therefore this time point was chosen to compare
binding levels in future experiments (Figure 2). Both the rate and
level of PC3 binding was higher to BME compared to HUVEC
with a significant difference (P = 0.006) already demonstrated
after 15 min incubation. The rate of adhesion to BMS was slower
than that observed to BME. A significant increase in the binding of
PC3 cells to BME versus BMS was found at 15 min (P = 0.025).
After 30 min there was no difference between the levels of adhe-
sion. The binding of PC3 cells to different endothelium or stroma
following a 1 h incubation is summarized in Figure 3. They
showed significantly greater adhesion to bone marrow endothe-
lium and bone marrow stroma compared to endothelium derived
from human umbilical vein endothelial cells (P = 0.008 and 0.009,
respectively). Binding to the lung endothelial cells (Hs888Lu)
was also significantly higher than to HUVEC (P = 0.00008).
Endothelial binding of the prostatic cell line, PNT2-C2, derived
from normal prostate tissue also showed a similar pattern to that of
PC3 cells (data not shown). 
To establish which adhesion molecules may be involved in the
binding of PC3 cells to BME, inhibitory antibodies against 
P-selectin, CD 31 and VCAM-1 were pre-incubated with bone
marrow endothelial cells prior to performing a binding assay.
Alternatively, the PC3 cells were pre-incubated with antibodies
directed against b4, b1, a2, a5, a4 integrins and sialy Lewis X
before carrying out a binding assay to BME. Figure 4 shows the
effect of using antibodies raised against adhesion molecules on
1420 LJ Scott et al 
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Table 1 Immunohistochemical staining of resting cells +++ = very strong
staining, ++ = strong staining, + = weak staining, +/ 2 = positive in some of
the cells and 2 = negative 
Antibody BME HUVEC PC3 
von Willebrand factor +++ +++ – 
P selectin +++ + – 
CD31 +/– +/– – 
Vimentin +++ ++ +++ 
Pan cytokeratin – – ++ 
UEA–1 ++ ++ – 
A
B
Figure 1 Immunohistochemical staining of cultured bone marrow
endothelial cells. (A) Negative control (mouse IgG1). UEA-1 coated magnetic
beads can be seen still attached to some of the cells, arrowhead, (B) von
Willebrand factor. Bar corresponds to 100 mm 
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Figure 2 Time course of PC3 binding to BME, BMS or HUVEC. 5 ´ 104
PC3 cells were added per well. PC3 binding is represented by optical density
of cytokeratin fluorescence. Data represent the mean of 3 experiments 
(6 replicas per assay), bars correspond to standard error of mean 
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Figure 3 Comparison of PC3 cells binding (5 ´ 104 per well) to various
endothelium or stroma after 1 h incubation. Data corresponds to mean of 3
experiments (6 replicas per assay), bars represent standard error of mean.
*= P <0.05 and **= P <0.001 (compared to binding to HUVEC) PC3 binding to BME. The antibody directed against b1 integrin
significantly inhibited (P = 0.000003) PC3 binding by 64%. None
of the other antibodies studied showed any marked reduction on
the epithelial:endothelial cell adhesion. 
Due to the interpatient heterogeneity observed in prostate cancer
(George, 1988), assays were repeated with 11 primary human
epithelial cell samples from patients with CaP or BPH. Our
previous experiments demonstrated very little binding of primary
cells (isolated from CaP or BPH tissue) after 1 h; maximum
binding was seen at 24 h (Lang et al, 1997). Although this differ-
ence was lost after one passage in culture (data not shown). We
therefore used 24 h as time point for subsequent experiments.
Primary epithelial cells from patients with CaP showed signifi-
cantly greater adhesion to BME and BMS compared to HUVEC 
(P = 0.00007 and P = 0.00003) (Figure 5A). The same was also
found for epithelia from BPH patients, P = 0.00002 and P = 0.008
(Figure 5B). Note that the large error bars are a reflection of
patient heterogeneity, however, all patients followed the same
binding trend. 
Invasion assay 
The ability of prostate epithelial cells (PNT2-C2, PC3 and epithe-
lial cells derived from patients with BPH) to invade through
matrigel invasion chambers in response to endothelial or BMS
cultures was assessed. Indirect co-culture of PNT2-C2 cells with
endothelium or stroma led to no significant increase in their inva-
sive ability compared to tissue culture plastic alone. The metastatic
cell line, PC3, showed an increase in invasion in response to BME
(231 cells/average field of view) and BMS (136 cells/average field
of view) but not to HUVEC (15 cells/average field of view)
compared to tissue culture plastic (16 cells/average field of
view). The increase in invasion in response to BME was signifi-
cantly greater than observed with BMS (P = 0.0437). None of the
BPH epithelial cells tested (n = 3) demonstrated any invasive
ability (Figure 6). 
DISCUSSION 
We have developed simple models to study the interactions of
prostatic epithelial cells with endothelium or stromal layers. These
assays have enabled us to establish that malignant and non-
malignant prostate epithelial cells preferentially adhere to bone
marrow endothelium at similar levels. Lehr and Pienta (1998) also
reported a 3-fold increase in binding to bone marrow endothelial
cells (albeit a cell line) compared to HUVEC. However, only the
malignant PC3 cells demonstrated increased invasion in response
to bone marrow endothelium. PC3 cells bound not only maximally
but their rate of binding was significantly faster to bone marrow
endothelium compared to bone marrow stroma and HUVEC. PC3
cells bound to a lung endothelium at an intermediate level between
HUVEC and bone marrow endothelium. As the lung is the third
commonest site for prostate metastases after lymph nodes and
bone marrow (Jacobs, 1983) our in vitro model appears to show a
similar pattern of metastatic selectivity to that found in vivo. It
would be of interest to expand our studies in the future to include
primary endothelial cells isolated from different organs such as
liver, kidney and brain. 
Human umbilical vein endothelial cells have been used in
several studies to look at tumour cell binding to endothelium
(Dejana et al, 1992; Majuri et al, 1992; Merwin et al, 1992; Iwai 
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Figure 4 Inhibition of PC3 binding to BME following pre-incubation (for 
30 min) with antibodies against cell adhesion molecules. Data demonstrates
mean for 3 experiments (3 replicas per assay), bars correspond to standard
error. **=P<0.001 compared to control (mouse IgG) 
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Figure 5 Binding of epithelial cells (5 ´ 104 per well) isolated from patients
with CaP (n = 11) to endothelium or stroma (A) and BPH (n = 11) (B).
Adhesion was allowed to take place for 24 h. Each patient sample was
measured in 3 individual experiments (3 replicas per assay) and the average
value calculated. Data represent the mean plus standard errors for the
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Figure 6 Invasion of prostate epithelial cells (PC3, PNT2-C2 or BPH)
through matrigel-coated invasion chambers in response to indirect HUVEC,
BME, BMS or tissue culture plastic (TCP). The data represent mean plus
standard error bars generated from 3 experiments (3 replicas per assay). 
**= P < 0.001 (compared to binding to HUVEC) et al, 1993; Takada et al, 1993; Zaifert and Cohen, 1993; Price et al,
1996; Kannagi, 1997). However, there are phenotypic and func-
tional differences between endothelial cells derived from large
vessels and those of the microvasculature (McCarthy et al, 1991).
Since tumour cell extravasation occurs generally within the
microvasculature (Alby and Auerbach, 1984) using large vessel
endothelium (such as HUVEC) may not be the best physiological
cell type to use as a model. Consequently, it is important to look at
tumour cell interactions with endothelium from their preferred
metastatic site in order to unravel the mechanism involved in the
process of metastasis. 
We have shown that the integrin b1 plays an important role in
the attachment of PC3 cells to bone marrow endothelium.
Increased expression of b1 has been linked with higher grades of
prostate cancer (Murant et al, 1997). Unlike the data observed with
PC3 binding to bone marrow stroma, antibodies against a2 did not
prevent PC3 binding to bone marrow endothelial cells. Antibodies
against b4, a4, a5, sialy Lewis X, CD31, P selecting and VCAM-
1 also demonstrated no inhibitory affects on adhesion. Jorgensen 
et al (1995) have linked the up-regulation of the oligosaccharide
sialy Lewis X with metastatic prostate cancer. However, a study by
Martensson and colleagues (Martensson et al, 1995) showed
strong expression of Lewis Y antigens in 26 out of 30 patients with
prostate cancer and only 5 showed non-sialy Lewis X. Benign
tissue was negative for Lewis Y and only the occasional cell was
positive for Lewis X. Our results indicate that sialy Lewis X is not
involved in the binding of the PC3 cell line to bone marrow
endothelium. Whether this will also be the case for primary
prostatic epithelial cells has yet to be established. These inhibition
data are conflicting to those reported by Lehr and Pienta (1998)
who found no inhibition using a b1 antibody in the binding of PC3
cells to a bone marrow endothelial cell line. They suggested a role
for galectin-3, a galactose-binding molecule, in PC3 binding.
Since we have not directly compared primary bone marrow
endothelial cells to their cell line the reasons for these differences
remain unknown. However, change of cell phenotype during
prolonged culture is a known and common feature. Changes in
adhesion molecule expression between immortalized and primary
bone marrow endothelial cells could therefore account for this
discrepancy. Another possibility is variations in commercial anti-
bodies that recognize different epitopes, which may or may not
inhibit cell adhesion in the assays used. 
Lectin:carbohydrate interactions may be involved in forming a
loose association to bone marrow endothelium with integrins
playing a more crucial role in securing strong adhesion. CD31 has
been shown to amplify b1-mediated adhesion to endothelial cells
(Tanaka et al, 1992). We found no inhibitory effects on PC3
binding to endothelial cells using a CD31-blocking antibody. A
synergistic effect could possibly occur by using anti-CD31 and
anti-b1 in combination. Price et al (1996) have demonstrated that
pre-treatment of a breast adenocarcinoma cell line and a
melanoma cell line with antibodies against b1 integrin substan-
tially inhibited their adhesion to HUVEC. They also showed that
simultaneous treatment of tumour and endothelial cells produced
an additive-blocking effect. A limited number of antibodies have
been used so far in these studies, other integrins such as a3, a6,
b3, avb3 or aIIbb3 may yet be found to be involved in prostate
epithelial cell interactions with bone marrow endothelial cells.
Indeed, aIIbb3 has recently been associated with prostate cancer
metastasis in a study of prostatic cell lines (Trikha et al, 1998). In
addition, the PC3 cell line has been shown to express avb3 and 16/16
primary CaP epithelial cells. Interestingly this adhesion molecule
was not found on normal prostatic epithelial cells (Zheng et al, 1999). 
It has been reported that there are differences in integrin expres-
sion between primary and metastatic prostate epithelial cells with
increased levels of b1, a2 and a6 being associated with higher
histological grades (Bonkhoff et al, 1993; Murant et al, 1997).
Variations in integrin expression are observed for different human
prostate cell lines in particular none expressed a4b1 and differ-
ences in a2b1 and a3b1 were observed (Rokhlin and Cohen,
1995). Also, we have found previously that there are variations in
the levels of inhibition of binding of prostate epithelial cells with
antibodies against a3 and a5 to bone marrow stroma (Lang et al,
1997). It is likely therefore that similar variations may be observed
when looking at binding to primary bone marrow endothelium.
Such differences are likely to be more relevant clinically than data
obtained using cell lines. 
For this reason we also thought it important to use primary
prostate samples in our experiments. The binding of primary
prostatic epithelial cells derived from CaP or BPH patients closely
mimicked that seen with PC3 cells, but the non-malignant PNT2-
C2 cell line was substantially less invasive in response to BME
than the metastatic cell line, PC3. In agreement none of the 3 BPH
samples tested demonstrated any invasive ability. Subtle differ-
ences may exist which affect the ability of these cells to
extravasate though a bone marrow endothelial barrier. Of the cells
that bind to bone marrow endothelium it is not known how many
would be capable of subsequent metastases formation. 
No differences were observed in the binding behaviour of
PNT2-C2 and PC3 or BPH and CaP prostatic epithelial cells to
BME. These results suggest that any prostate epithelial cell
entering the circulation has the potential to adhere to bone marrow
endothelium. Clearly, in vivo, not all circulating prostatic epithe-
lial cells adhere to endothelium and go on to invade and form
secondary tumours. There is evidence to support this as large
numbers of epithelial cells are released into the circulation during
prostatic resection without any adverse effects on the patients
overall survival (Arcangeli et al, 1995). Our recent data suggest
therefore that the invasive nature of malignant versus non-malig-
nant epithelial cells may be a critical step in the formation of
metastasis. It is essential to explore these differences further since
both BPH and CaP cells show growth stimulation in response to
bone marrow stroma (Lang et al, 1998). Using the cellular models
described here we hope to study the molecular nature of the inter-
action of prostate epithelia and bone marrow endothelia, in partic-
ular the changes required for invasion. 
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